Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Intravenous immunoglobulin (IVIG) is a fractioned blood product consisting of IgG antibodies which was first used in antibody deficiency disorders. It is increasingly being used for several inflammatory and autoimmune conditions. IVIG can also be used in a wide range of dermatological diseases which are difficult to treat including autoimmune bullous skin diseases and toxic epidermal necrolysis. The use of IVIG in dermatological disorders is discussed in this article.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/1871528111312020007 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!